Derivative Liabilities - Fair Value
Pfizer Derivative Liabilities - Fair Value decreased by 6.4% to $1.37B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.9%, from $1.31B to $1.37B. Over 5 years (FY 2020 to FY 2025), Derivative Liabilities - Fair Value shows an upward trend with a 5.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase in liabilities suggests unfavorable market movements for the company's hedges, while a decrease indicates a reduction in potential settlement obligations.
Detailed definition
This represents the fair value of derivative financial instruments that are currently in a liability position. These lia...
Peer comparison
Standard for energy companies; peers with similar hedging profiles will show comparable volatility in this line item.
derivative_liabilities_fair_valueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $959.00M | $823.00M | $881.00M | $930.00M | $1.29B | $1.78B | $1.89B | $1.49B | $1.61B | $1.47B | $1.42B | $1.15B | $1.23B | $1.51B | $1.37B | $1.31B | $1.91B | $1.58B | $1.46B | $1.37B |
| QoQ Change | — | -14.2% | +7.0% | +5.6% | +38.8% | +37.6% | +6.3% | -21.2% | +7.9% | -8.6% | -3.3% | -19.3% | +7.2% | +22.8% | -9.4% | -3.8% | +45.4% | -17.5% | -7.5% | -6.4% |
| YoY Change | — | — | — | — | +34.6% | +115.9% | +114.4% | +60.0% | +24.4% | -17.4% | -24.8% | -23.0% | -23.5% | +2.7% | -3.8% | +14.7% | +55.6% | +4.6% | +6.7% | +3.9% |
Derivative Liabilities - Fair Value at Other Companies
Frequently Asked Questions
- What is Pfizer's derivative liabilities - fair value?
- Pfizer (PFE) reported derivative liabilities - fair value of $1.37B in Q1 2026.
- How has Pfizer's derivative liabilities - fair value changed year-over-year?
- Pfizer's derivative liabilities - fair value increased by 3.9% year-over-year, from $1.31B to $1.37B.
- What is the long-term trend for Pfizer's derivative liabilities - fair value?
- Over 5 years (2020 to 2025), Pfizer's derivative liabilities - fair value has grown at a 5.8% compound annual growth rate (CAGR), from $1.10B to $1.46B.
- What does derivative liabilities - fair value mean?
- The total market value of all derivative contracts that are currently resulting in a loss.